Related Experiment Video
Updated: Mar 29, 2026

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level
Published on: November 2, 2020
Extracellular high-mobility group box 1 mediates pressure overload-induced cardiac hypertrophy and heart failure
Lei Zhang1, Ming Liu1, Hong Jiang1
1Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Shanghai Medical College of Fudan University, Shanghai, China.
Insights
High-mobility group box 1 (HMGB1) exacerbates cardiac hypertrophy and dysfunction following pressure overload. Inhibiting HMGB1 partially reverses these detrimental effects, highlighting its role in heart injury.
Area of Science:
- Cardiovascular Biology
- Molecular Medicine
- Inflammation Research
Background:
- Inflammation is critical in pressure overload-induced cardiac hypertrophy and heart failure.
- The precise mechanisms remain unclear, but High-mobility group box 1 (HMGB1) is elevated in the myocardium under pressure overload and may contribute to cardiac injury.
Purpose of the Study:
- To investigate the role of HMGB1 in cardiac hypertrophy and dysfunction induced by pressure overload.
- To explore HMGB1's involvement in myocardial response to mechanical stress.
Main Methods:
- Pressure overload was induced in mice via transverse aortic constriction (TAC).
- Recombinant HMGB1 or HMGB1 antagonist was administered, alongside echocardiography and histological analysis.
- Cardiac myocytes were subjected to mechanical stress in vitro, with HMGB1 expression and release analyzed.
Main Results:
- TAC increased cardiac HMGB1 expression and translocation.
- Exogenous HMGB1 worsened TAC-induced cardiac hypertrophy and dysfunction.
- HMGB1 inhibition partially reversed TAC-induced pathological changes.
- Mechanical stress stimulated HMGB1 release and synthesis in cultured cardiac myocytes.
Conclusions:
- Activated and upregulated HMGB1 in the myocardium, partly from cardiac myocytes, is crucial in pressure overload-induced cardiac hypertrophy and dysfunction.
- HMGB1 is a significant mediator of cardiac injury under pressure overload conditions.
Abstract:
Inflammation plays a key role in pressure overload-induced cardiac hypertrophy and heart failure, but the mechanisms have not been fully elucidated. High-mobility group box 1 (HMGB1), which is increased in myocardium under pressure overload, may be involved in pressure overload-induced cardiac injury. The objectives of this study are to determine the role of HMGB1 in cardiac hypertrophy and cardiac dysfunction under pressure overload. Pressure overload was imposed on the heart of male wild-type mice by transverse aortic constriction (TAC), while recombinant HMGB1, HMGB1 box A (a competitive antagonist of HMGB1) or PBS was injected into the LV wall. Moreover, cardiac myocytes were cultured and given sustained mechanical stress. Transthoracic echocardiography was performed after the operation and sections for histological analyses were generated from paraffin-embedded hearts. Relevant proteins and genes were detected. Cardiac HMGB1 expression was increased after TAC, which was accompanied by its translocation from nucleus to both cytoplasm and intercellular space. Exogenous HMGB1 aggravated TAC-induced cardiac hypertrophy and cardiac dysfunction, as demonstrated by echocardiographic analyses, histological analyses and foetal cardiac genes detection. Nevertheless, the aforementioned pathological change induced by TAC could partially be reversed by HMGB1 inhibition. Consistent with the in vivo observations, mechanical stress evoked the release and synthesis of HMGB1 in cultured cardiac myocytes. This study indicates that the activated and up-regulated HMGB1 in myocardium, which might partially be derived from cardiac myocytes under pressure overload, may be of crucial importance in pressure overload-induced cardiac hypertrophy and cardiac dysfunction.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Heart Failure II: Pathophysiology
Pathophysiology of Heart Failure
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy II: Dilated Cardiomyopathy
Mitral Regurgitation I: Introduction

